Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | IMC-F106C |
Trade Name | |
Synonyms | IMC F106C|IMC F106C|Brenetafusp |
Drug Descriptions |
IMC-F106C is a bispecific fusion protein targeting CD3 and PRAME, which potentially results in antitumor activity (Ann Oncol (2022) 33 (suppl_7): S875). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C170976 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Gemcitabine + IMC-F106C | Gemcitabine IMC-F106C | 0 | 0 |
IMC-F106C | IMC-F106C | 0 | 1 |
IMC-F106C + Nab-paclitaxel | IMC-F106C Nab-paclitaxel | 0 | 0 |
IMC-F106C + Nivolumab | IMC-F106C Nivolumab | 0 | 1 |
IMC-F106C + Pegylated liposomal doxorubicin | IMC-F106C Pegylated liposomal doxorubicin | 0 | 0 |
IMC-F106C + unspecified PD-1 antibody | IMC-F106C unspecified PD-1 antibody | 0 | 1 |
IMC-F106C + unspecified PD-L1 antibody | IMC-F106C unspecified PD-L1 antibody | 0 | 1 |